BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company's cell+gene platform is harnessing the power of cells to create a pipeline of new medicines for patients suffering from neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock's lead clinical program, bemdaneprocel, (BRT-DA01) is in Phase 1 clinical trials for Parkinson’s disease. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and became a wholly owned, independently operated subsidiary of Bayer AG in late 2019 as a cornerstone of its newly formed Cell & Gene Therapy Platform.